Horizon still has a mountain to climb
But positive mid-stage Sjögren’s data raise hopes for others still plugging away at anti-CD40 assets.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Kezar gets a second chance
However, data with zetomipzomib in lupus nephritis are not quite as good as they first appear.
